Similar comparisons have not yet been made. For example, Irish-based jazz pharmaceuticals and Danish pharmaceutical company Lundbeck said they had in principle entered into agreements for non-profit foundations to help patients. In its stock release, Jazz said it set aside $57 million, while Lundbeck said he expected to pay $52.6 million. Other pharmaceutical companies that have received subpoenas include Astellas Pharma, Biogen, Celgene, Gilead Sciences, Johnson-Johnson and Valeant Pharmaceuticals. Ut also entered into a Business Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG). Among other things, the five-year CIA requires UT to implement measures to ensure that agreements and interactions with third-party patient assistance programs are in compliance with the law. In addition, the CIA requires audits through an independent monitoring organization, compliance certifications of executives and board members, and the implementation of a risk assessment and mitigation process. “Our Business Integrity Agreement requires United Therapeutics to establish controls and oversight to promote true independence from all patient assistance programs for which it donates,” said Gregory E. Demske, Head of General Screening at the U.S.
Department of Health. “In the absence of true independence, a pharmaceutical company can use a foundation as a channel for inappropriate payments that expose the taxpayer-funded Medicare program to the risk of abuse.” AmerisourceBergen`s five-year Enterprise Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (OIG) provides compliance officials with a roadmap of best practices, including: implementing surveillance and audit controls. The Compliance Department should oversee donations to independent charitable PAPs each year by adopting both a risk-based approach to targeting and a random approach to sampling. The documentation to be reviewed includes budget documents; Documents relating to the donation decision-making process; and all written agreements, as well as any communication and interaction between the company and the independent charity PAP. United sells anti-HAP drugs, including Adcirca, Remodulin, Tyvaso and Orenitram; Last year, the drug maker had total sales of $1.6 billion. As part of the transaction, the company entered into a five-year contract with HHS-OIG on the integrity of the company. “UT used a third party to do exactly what he knew he couldn`t legitimately do himself,” said current U.S. Attorney William D.
Weinreb. “Following the allegations made in today`s transaction agreement, UT understood that the third-party foundation had used UT money to cover the co-payments of patients taking UT drugs. UT`s payments to the Foundation were not charitable payments for patients with HT in general, but were a way to give money to patients taking UT drugs.